203 related articles for article (PubMed ID: 24889897)
1. Antagonizing STAT3 dimerization with a rhodium(III) complex.
Ma DL; Liu LJ; Leung KH; Chen YT; Zhong HJ; Chan DS; Wang HM; Leung CH
Angew Chem Int Ed Engl; 2014 Aug; 53(35):9178-82. PubMed ID: 24889897
[TBL] [Abstract][Full Text] [Related]
2. Group 9 organometallic compounds for therapeutic and bioanalytical applications.
Ma DL; Chan DS; Leung CH
Acc Chem Res; 2014 Dec; 47(12):3614-31. PubMed ID: 25369127
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Palepu NR; Nongbri SL; Premkumar JR; Verma AK; Bhattacharjee K; Joshi SR; Forbes S; Mozharivskyj Y; Thounaojam R; Aguan K; Kollipara MR
J Biol Inorg Chem; 2015 Jun; 20(4):619-38. PubMed ID: 25712889
[TBL] [Abstract][Full Text] [Related]
4. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
[TBL] [Abstract][Full Text] [Related]
5. Interaction of ferrocene appended Ru(II), Rh(III) and Ir(III) dipyrrinato complexes with DNA/protein, molecular docking and antitumor activity.
Paitandi RP; Gupta RK; Singh RS; Sharma G; Koch B; Pandey DS
Eur J Med Chem; 2014 Sep; 84():17-29. PubMed ID: 25014746
[TBL] [Abstract][Full Text] [Related]
6. A rhodium(III)-based inhibitor of autotaxin with antiproliferative activity.
Kang TS; Wang W; Zhong HJ; Liang JX; Ko CN; Lu JJ; Chen XP; Ma DL; Leung CH
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):256-263. PubMed ID: 27888146
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes.
Guo L; Hu X; Yang Y; An W; Gao J; Liu Q; Liu Z
Bioorg Chem; 2021 Nov; 116():105311. PubMed ID: 34474302
[TBL] [Abstract][Full Text] [Related]
8. Improved antiparasitic activity by incorporation of organosilane entities into half-sandwich ruthenium(II) and rhodium(III) thiosemicarbazone complexes.
Adams M; de Kock C; Smith PJ; Land KM; Liu N; Hopper M; Hsiao A; Burgoyne AR; Stringer T; Meyer M; Wiesner L; Chibale K; Smith GS
Dalton Trans; 2015 Feb; 44(5):2456-68. PubMed ID: 25559246
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
10. Rhodium, iridium, and ruthenium half-sandwich picolinamide complexes as anticancer agents.
Almodares Z; Lucas SJ; Crossley BD; Basri AM; Pask CM; Hebden AJ; Phillips RM; McGowan PC
Inorg Chem; 2014 Jan; 53(2):727-36. PubMed ID: 24397747
[TBL] [Abstract][Full Text] [Related]
11. Thermally inert metal ammines as light-inducible DNA-targeted agents. Synthesis, photochemistry, and photobiology of a prototypical rhodium(III)-intercalator conjugate.
Barry CG; Turney EC; Day CS; Saluta G; Kucera GL; Bierbach U
Inorg Chem; 2002 Dec; 41(26):7159-69. PubMed ID: 12495358
[TBL] [Abstract][Full Text] [Related]
12. Electrochemical detection of the Fc-STAT3 phosphorylation and STAT3-Fc-STAT3 dimerization and inhibition.
Martic S; Rains MK; Haftchenary S; Shahani VM; Kraskouskaya D; Ball DP; Gunning PT; Kraatz HB
Mol Biosyst; 2014 Mar; 10(3):576-80. PubMed ID: 24402062
[TBL] [Abstract][Full Text] [Related]
13. Thiabendazole-based Rh(III) and Ir(III) biscyclometallated complexes with mitochondria-targeted anticancer activity and metal-sensitive photodynamic activity.
Pérez-Arnaiz C; Acuña MI; Busto N; Echevarría I; Martínez-Alonso M; Espino G; García B; Domínguez F
Eur J Med Chem; 2018 Sep; 157():279-293. PubMed ID: 30099251
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer activity of cyclic amine and thiaether metal complexes.
Medvetz DA; Stakleff KD; Schreiber T; Custer PD; Hindi K; Panzner MJ; Blanco DD; Taschner MJ; Tessier CA; Youngs WJ
J Med Chem; 2007 Apr; 50(7):1703-6. PubMed ID: 17343369
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
Nishisaka F; Taniguchi K; Tsugane M; Hirata G; Takagi A; Asakawa N; Kurita A; Takahashi H; Ogo N; Shishido Y; Asai A
Cancer Sci; 2020 May; 111(5):1774-1784. PubMed ID: 32112605
[TBL] [Abstract][Full Text] [Related]
16. Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity.
Minus MB; Liu W; Vohidov F; Kasembeli MM; Long X; Krueger MJ; Stevens A; Kolosov MI; Tweardy DJ; Sison EA; Redell MS; Ball ZT
Angew Chem Int Ed Engl; 2015 Oct; 54(44):13085-9. PubMed ID: 26480340
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of new polynuclear organometallic Ru(II), Rh(III) and Ir(III) pyridyl ester complexes as in vitro antiparasitic and antitumor agents.
Chellan P; Land KM; Shokar A; Au A; An SH; Taylor D; Smith PJ; Riedel T; Dyson PJ; Chibale K; Smith GS
Dalton Trans; 2014 Jan; 43(2):513-26. PubMed ID: 24121555
[TBL] [Abstract][Full Text] [Related]
18. Design of luminescent biotinylation reagents derived from cyclometalated iridium(III) and rhodium(III) bis(pyridylbenzaldehyde) complexes.
Leung SK; Kwok KY; Zhang KY; Lo KK
Inorg Chem; 2010 Jun; 49(11):4984-95. PubMed ID: 20465281
[TBL] [Abstract][Full Text] [Related]
19. Increasing anti-cancer activity with longer tether lengths of group 9 Cp* complexes.
Lucas SJ; Lord RM; Basri AM; Allison SJ; Phillips RM; Blacker AJ; McGowan PC
Dalton Trans; 2016 Apr; 45(16):6812-5. PubMed ID: 26924272
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents.
Lucas SJ; Lord RM; Wilson RL; Phillips RM; Sridharan V; McGowan PC
Dalton Trans; 2012 Dec; 41(45):13800-2. PubMed ID: 23015068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
